secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001213900-24-020440
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial raises $3.5M via warrant exercise, issues new 2.3M-share warrants
-----------------------------------------------------------------------

- Gross proceeds of ~$3.5M from cash exercise of 1.15M existing warrants at $2.82/share; H.C. Wainwright placement agent.
- Incentive: new unregistered Series C warrants to buy up to 2.3M shares at $2.82, exercisable for 18 months.
- Holder paid $0.125 per new warrant; placement agent fees: 7% cash + 1% management + $25k expense + $50k legal.
- Proceeds to fund working capital and clinical activities for lead drug AD04 targeting Alcohol Use Disorder.
- Company to file resale registration statement for new warrant shares within 45 days of closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024020440/0001213900-24-020440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390024020440/ea0201235-8k_adialpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-020440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer